Santos-García, D.; López-Manzanares, L.; Muro, I.; Lorenzo-Barreto, P.; Casas Peña, E.; García-Ramos, R.; Fernández Valle, T.; Morata-Martínez, C.; Baviera-Muñoz, R.; Martínez-Torres, I.;
et al. Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson’s Disease. Brain Sci. 2024, 14, 1244.
https://doi.org/10.3390/brainsci14121244
AMA Style
Santos-García D, López-Manzanares L, Muro I, Lorenzo-Barreto P, Casas Peña E, García-Ramos R, Fernández Valle T, Morata-Martínez C, Baviera-Muñoz R, Martínez-Torres I,
et al. Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson’s Disease. Brain Sciences. 2024; 14(12):1244.
https://doi.org/10.3390/brainsci14121244
Chicago/Turabian Style
Santos-García, Diego, Lydia López-Manzanares, Inés Muro, Pablo Lorenzo-Barreto, Elena Casas Peña, Rocío García-Ramos, Tamara Fernández Valle, Carlos Morata-Martínez, Raquel Baviera-Muñoz, Irene Martínez-Torres,
and et al. 2024. "Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson’s Disease" Brain Sciences 14, no. 12: 1244.
https://doi.org/10.3390/brainsci14121244
APA Style
Santos-García, D., López-Manzanares, L., Muro, I., Lorenzo-Barreto, P., Casas Peña, E., García-Ramos, R., Fernández Valle, T., Morata-Martínez, C., Baviera-Muñoz, R., Martínez-Torres, I., Álvarez-Sauco, M., Alonso-Modino, D., Legarda, I., Valero-García, M. F., Suárez-Muñoz, J. A., Martínez-Castrillo, J. C., Perona, A. B., Salom, J. M., Cubo, E.,
... Alvarez-Santullano, M. M.
(2024). Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson’s Disease. Brain Sciences, 14(12), 1244.
https://doi.org/10.3390/brainsci14121244
